Øvretveit Karsten, Klevjer Marie, Brumpton Ben M, Wisløff Ulrik, Hveem Kristian, Bye Anja
HUNT Center for Molecular and Clinical Epidemiology (MCE), Department of Public Health and Nursing, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Department of Education and Sports Science, University of Stavanger, Stavanger, Norway.
medRxiv. 2025 Jul 7:2025.07.07.25330991. doi: 10.1101/2025.07.07.25330991.
Cardiorespiratory fitness (CRF) has a strong genetic component and low CRF is a major risk factor for cardiovascular morbidity and mortality. The purpose of this study was to develop and validate a polygenic score (PGS) for CRF (CRF) and assess its associations with cardiovascular disease (CVD) and all-cause mortality. We hypothesized that the CRF would demonstrate similar cardioprotective benefits as the CRF phenotype.
Effect estimates from a genome-wide association study on directly measured CRF in the Trøndelag Health Study (HUNT; = 4 525) were used in a Bayesian regression framework to develop multiple PGSs in an independent cohort from the UK Biobank ( = 65 165). The top performing score was applied in the HUNT target cohort, excluding the discovery sample ( = 82 109).
The PGS-CRF association varied considerably as a function of model fit and phenotypic accuracy. In the target population, we observed a difference in CRF of 1.55 [95% confidence interval: 1.26, 1.84] mL·kg·min between the bottom and top decile of the CRF. Moreover, a high CRF demonstrated cardioprotective effects, with reduced risk for CVD, myocardial infarction, hypertension, and all-cause mortality. We also found that the CRF predisposed to lower risk of heart failure and hypertrophic cardiomyopathy in women.
A PGS for CRF derived from gold-standard phenotypes captures small, but potentially clinical meaningful variations in CRF, and is associated with reduced risk of cardiovascular morbidity and mortality. Heterogeneity in CRF phenotyping in large populations remains a challenge to PGS development and refinement.
心肺适能(CRF)具有很强的遗传成分,而低心肺适能是心血管疾病发病和死亡的主要危险因素。本研究的目的是开发并验证一种用于心肺适能(CRF)的多基因评分(PGS),并评估其与心血管疾病(CVD)和全因死亡率的关联。我们假设CRF多基因评分将显示出与CRF表型相似的心脏保护益处。
在特隆赫姆健康研究(HUNT;n = 4525)中,基于直接测量的CRF进行全基因组关联研究的效应估计,用于贝叶斯回归框架,以在英国生物银行的一个独立队列(n = 65165)中开发多个PGS。表现最佳的评分应用于HUNT目标队列,但不包括发现样本(n = 82109)。
PGS-CRF关联因模型拟合和表型准确性而有很大差异。在目标人群中,我们观察到CRF多基因评分最低和最高十分位数之间的CRF差异为1.55 [95%置信区间:1.26, 1.84] mL·kg·min。此外,高CRF显示出心脏保护作用,心血管疾病、心肌梗死、高血压和全因死亡率的风险降低。我们还发现,CRF多基因评分使女性患心力衰竭和肥厚型心肌病的风险降低。
源自金标准表型的CRF多基因评分捕捉到了CRF中虽小但可能具有临床意义的变异,并且与心血管疾病发病和死亡风险降低相关。大量人群中CRF表型的异质性仍然是PGS开发和完善的一个挑战。